Have a feature idea you'd love to see implemented?
Let us know!
EQ Equillium Inc
Price (delayed)
$0.72
Market cap
$25.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$10.56M
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing
Highlights
The quick ratio has soared by 57% YoY and by 44% from the previous quarter
The EPS has increased by 46% since the previous quarter and by 41% year-on-year
The equity has contracted by 3.9% YoY but it has grown by 3.3% from the previous quarter
Key stats
What are the main financial stats of EQ
Market
Valuations
Earnings
Shares outstanding
35.43M
Market cap
$25.51M
Enterprise value
$10.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.23
Revenue
$45.91M
EBIT
-$4.6M
EBITDA
-$4.46M
Free cash flow
-$21.51M
Per share
Balance sheet
Liquidity
EPS
-$0.13
Free cash flow per share
-$0.61
Book value per share
$0.65
Revenue per share
$1.3
TBVPS
$0.97
Total assets
$34.46M
Total liabilities
$11.28M
Debt
$497,000
Equity
$23.18M
Working capital
$22.59M
Debt to equity
0.02
Current ratio
3.04
Quick ratio
2.79
Net debt/EBITDA
3.35
Margins
Efficiency
Dividend
EBITDA margin
-9.7%
Gross margin
100%
Net margin
-10.1%
Operating margin
-14.7%
Return on assets
-10.8%
Return on equity
-20.7%
Return on invested capital
-57.9%
Return on capital employed
-19.7%
Return on sales
-10%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EQ stock price
How has the Equillium stock price performed over time
Intraday
0.26%
1 week
5.23%
1 month
-35.71%
1 year
44.35%
YTD
-0.41%
QTD
-13.46%
Financial performance
How have Equillium's revenue and profit performed over time
Revenue
$45.91M
Gross profit
$45.91M
Operating income
-$6.77M
Net income
-$4.62M
Gross margin
100%
Net margin
-10.1%
Equillium's net margin has increased by 48% QoQ and by 48% YoY
EQ's net income is up by 45% since the previous quarter and by 44% year-on-year
EQ's operating margin is up by 36% from the previous quarter and by 33% YoY
The operating income is up by 30% since the previous quarter and by 27% year-on-year
Growth
What is Equillium's growth rate over time
Valuation
What is Equillium stock price valuation
P/E
N/A
P/B
1.1
P/S
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.23
The EPS has increased by 46% since the previous quarter and by 41% year-on-year
The price to book (P/B) is 39% lower than the last 4 quarters average of 1.8 and 35% lower than the 5-year quarterly average of 1.7
The equity has contracted by 3.9% YoY but it has grown by 3.3% from the previous quarter
The stock's P/S is 44% less than its last 4 quarters average of 1.0
Equillium's revenue has increased by 8% from the previous quarter and by 8% YoY
Efficiency
How efficient is Equillium business performance
The ROIC has soared by 69% since the previous quarter and by 50% year-on-year
The return on sales has increased by 45% since the previous quarter and by 38% year-on-year
The ROE has grown by 44% from the previous quarter and by 29% YoY
The company's return on assets rose by 38% QoQ and by 13% YoY
Dividends
What is EQ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EQ.
Financial health
How did Equillium financials performed over time
EQ's total liabilities has plunged by 64% YoY and by 45% from the previous quarter
The company's current ratio has surged by 59% YoY and by 46% QoQ
Equillium's debt is 98% lower than its equity
EQ's debt to equity has dropped by 50% year-on-year and by 33% since the previous quarter
Equillium's debt has decreased by 46% YoY and by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.